Dexcel Pharma Technologies Ltd., 10% Owner at Urovant Sciences Ltd. (UROV), bought 18,369 shares at $8.21 ($151K) on 2019-06-18, disclosed to the SEC on 2019-06-19.
Open-market purchase of $151k UROV by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.21 | 6,706 | $55K | 36.6% |
| 2 | $8.21 | 6,706 | $55K | 36.6% |
| 3 | $8.17 | 4,957 | $40K | 26.9% |
| Total | $8.20 avg | 18,369 | $151K | 100% |
| Filing → |
| UROV | BUY | 2019-06-14 | $355K | — | Filing → |
| UROV | BUY | 2019-06-11 | $292K | — | Filing → |
| MYOV | BUY | 2019-06-06 | $40.0M | — | Filing → |